ZVSA · ZyVersa Therapeutics, Inc.
$0.10
+0.00 (+0.00%)
At close · Aug 17
Going-concern doubt
— flagged May 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These uncertainties raise substantial doubt about our ability to continue as a going concern for 12 months after the issuance date of our financial statements.”View the 10-Q filed May 13, 2026
Market Cap
$801,496
Shares
8.10M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$24.95M
-165.1%
FY2025
Diluted EPS
-$4.18
+50.7%
FY2025
Operating Cash Flow
-$5.11M
+32%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| -$526.16K | -$513.21K | -$269.86K | $457 | — | — | |
| $911.85K | $1.11M | $1.78M | $3.21M | $399.89K | — | |
| $5.09M | $5.73M | $7.36M | $11.21M | $420.17K | — | |
| $24.65M | $25.49M | $9.14M | $107.75M | $820.07K | — | |
| -$24.65M | -$25.49M | -$9.14M | -$107.75M | -$820.07K | -$235.27K | |
| — | -$25.8M | -$9.41M | -$107.75M | — | — | |
| — | -$851.66K | $6745 | -$9.46M | -$745.05K | — | |
| -$24.49M | -$24.95M | -$9.41M | -$98.3M | -$75.02K | -$240.7K | |
| — | — | -$9.41M | -$106.25M | -$75.02K | — | |
| USD/shares | — | -$4.18 | -$8.48 | -$1,089.70 | -$3.50 | — |
| USD/shares | — | -$4.18 | -$8.48 | -$1,089.70 | — | — |
| shares | — | 5.96M | 1.11M | 97.5K | 25.76K | — |
| shares | — | 5.96M | 1.11M | 97.5K | — | — |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 1.52×
EV/EBIT
—
P/E (TTM)
—
Peer medians compare against the 67 similar-size Biotechnology companies (of 545 listed).